Independent clinical laboratory industry has experienced less than 20 years’ development in China, but there were more than 110 independent clinical laboratories in China with rapid development. Kingmed, Adicon and Dian placed on the top three respectively among large-scale chain-store clinical laboratories. Market scale was approximately CNY 2.5 billion in 2012, only accounting for about 1.5% of market shares in clinical laboratory industry currently. But in America, independent clinical laboratory industry accounted for one third of market shares, so there is still a big gap when compared with America. Huidian Research takes a view that sales value of Kingmed firstly broke through CNY 1 billion as of 2012, which can be deemed as China independent clinical laboratory industry entered rapid-growth period.
Under the background of new medical reform, independent clinical laboratory industry will further expand so as to enter rapid-growth period. During this period, increasing new entrants will step into this industry, chain enterprises and solo independent laboratory will coexist. But in the long run, chain enterprises are equipped with the capacities of large-scale purchase and standard management and administration for reducing production costs; service network layout will obtain brand effect for attracting customers. However, the service of solo independent laboratory is limited within 400 kilometers, customer resources are inclined to be saturated. In addition, it will drop out the market along with losses because of declined prices. Thus chain enterprises are expected to be still prosperous.
Through comparing testing project reserves, layout of service network station and management and administration capability in domestic chain enterprises, Huidian Research holds a view of Kingmed owns absolute competitive advantages and will keep its leading position in industry due to high-end project reserves and many laboratories are widely distributed; Adicon and Dian placed on the second, Adicon has high-end project reserves and strict quality control standards, while Dian owns differentiation competitive advantages such as level-to-level administration laboratories, increase output and “ agency + service ” mode for reducing purchasing costs etc.; DAAN Gene started late (2007), so it is slightly inferior to the other three enterprises.
“Research and Development Trend of China Independent Clinical Laboratory Market, 2013-2017” mainly conducts an in-depth market research on development environment and market status quo of China independent clinical laboratory industry, makes an analysis of domestic market status quo, supply and demand, upstream and downstream industries and business performance of key enterprises, meanwhile makes a forecast for the industry so as to provide a decision-making reference for enterprises to understand and invest such industry.
1. Overview of Independent Clinical Laboratory
1.1 Definition
1.2 Business Pattern
1.3 Technological Level and Technical Characteristics
2. Development History of Independent Clinical Laboratory Industry
2.1 Development Status Quo of Foreign Independent Clinical Laboratory
2.1.1 Background
2.1.2 Development of American Independent Clinical Laboratory
2.2 Development of China’s Independent Clinical Laboratory
3. Development Environment of Independent Clinical Laboratory
3.1 Cost Control in Public Hospital
3.2 Increased Treatments in Basic Medical Institutions
3.3 Rapid Development of Private Hospitals
3.4 Industry Supervision System
3.5 Policies and Major Regulations
4. Development of China Independent Clinical Laboratory Industry
4.1 Status Quo of China Independent Clinical Laboratory Market
4.1.1 Market Capacity
4.1.2 Competitive Landscape
4.1.3 Marketization Degree
4.1.4 Changing Trend of Profit and Reasons
4.1.5 Michael Porter’s Five Forces Model
4.2 Market Supply and Demand of China Independent Clinical Laboratory and Influencing Factors
4.3 Upstream Industry and Downstream Industry
4.3.1 Upstream Industry’s Impact on Independent Clinical Laboratory Industry
4.3.2 Downstream Industry’s Impact on Independent Clinical Laboratory Industry
4.4 Barriers to Entry
4.4.1 Barrier of Access
4.4.2 Quality Control
4.4.3 Technical Barrier
4.4.4 Professional Talents
4.5 Development Factors
4.5.1 Favorable Factors
4.5.2 Negative Factors
5. Key Enterprises of China Independent Clinical Laboratory
5.1 Kingmed Diagnostics
5.1.1 Company Profile
5.1.2 Service Network
5.1.3 Business Performance
5.1.4 Management and Administration Mode
5.1.5 Future Development Strategy
5.2 Dian Diagnostics
5.2.1 Company Profile
5.2.2 Business Performance
5.2.3 Business Composition Analysis
5.2.4 Major Suppliers
5.2.5 Competitive Advantages
5.2.6 Future Development Strategy and Business Plan in 2013
5.3 DAAN Gene Co., Ltd.
5.3.1 Company Profile
5.3.2 Business Performance
5.3.3 Revenue Composition
5.3.4 Suppliers
5.3.5 Competitive Advantages
5.4 Adicon
5.4.1 Company Profile
5.4.2 Business Performance
5.4.3 Future Development Strategy
6. Future Development of China Independent Clinical Laboratory
6.1 Future Development Trend
6.1.1 “12th Five-Year” Plan New Medical Reform Policy Brings Opportunities
6.1.2 Continuous Rapid Growth of Medical Service Industry Promote Independent Clinical Laboratory Service Industry
6.1.3 New Diagnostic Techniques Motive Independent Clinical Laboratory Service Industry
6.2 Challenges and Opportunities
6.3 More Market Shares and Structure Upgrade
